Skip to content
Screener

Total Equity at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$3.41B+34.4%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$705.78M+11.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.28B-38.2%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$437.76M+85.9%
XER
Xeris Biopharma Holdings, Inc.XERS
-$9.73M+49.6%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$501.92M-40.7%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemMarch 31,2026December 31,2025
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 20252,828,2042,407,757
Accumulated other comprehensive (loss) income(1,254)1,865
Accumulated deficit(1,545,272)(1,417,427)
Stock held in trust(1,032)(112)
TOTAL STOCKHOLDERS’ EQUITY1,280,646992,083
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$1,401,323$1,126,257

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's total equity?
Crinetics Pharmaceuticals (CRNX) reported total equity of $1.28B in Q1 2026.
How has Crinetics Pharmaceuticals's total equity changed year-over-year?
Crinetics Pharmaceuticals's total equity increased by 2.1% year-over-year, from $1.25B to $1.28B.
What is the long-term trend for Crinetics Pharmaceuticals's total equity?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's total equity has grown at a 42.5% compound annual growth rate (CAGR), from $168.92M to $992.08M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Crinetics Pharmaceuticals's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude